Literature DB >> 20673598

Outcomes and management costs in patients hospitalized for skin and skin-structure infections.

Kamal M F Itani1, Sanjay Merchant, Swu-Jane Lin, Kasem Akhras, Juan Carlos Alandete, Hind T Hatoum.   

Abstract

BACKGROUND: This study was conducted to determine outcomes and costs of treating complicated skin and skin-structure infections (cSSSIs) due to gram-positive only, gram-negative only, or mixed pathogens (gram-positive and gram-negative), including those with methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa.
METHODS: Data on length of stay (LOS), mortality, and charges for cSSSIs were compiled from claims in the multihospital Solucient database from 2002 to 2006.
RESULTS: Among the 5156 cases with pathogens identified, 59.7% were gram-positive, 21.5% were gram-negative, and 18.8% were mixed. Patients with mixed pathogens incurred significantly higher LOS (17.2 days), mortality (10.2%), and charges ($80,093) than those with cSSSIs due to gram-negative pathogens (10.1 days, 6.5%, and $41,634, respectively) or to gram-positive pathogens (9.5 days, 4.8%, and $40,046, respectively). MRSA was isolated from 21.6% of all cases and from 26.3% of cases involving mixed pathogens. MRSA cases had significantly longer LOS and greater mortality than non-MRSA cases, but similar total charges. P aeruginosa occurred in 13.3% of all cases and in 36.3% of cases involving mixed pathogens. P aeruginosa cases had significantly higher LOS and charges compared with non‒P aeruginosa cases.
CONCLUSION: Although gram-positive pathogens were the most common causes of cSSSIs, cases involving mixed and resistant pathogens were associated with longer LOS, greater mortality, and higher total charges. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673598     DOI: 10.1016/j.ajic.2010.03.018

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  17 in total

1.  Microbiology of the infected recurrent sacrococcygeal pilonidal sinus.

Authors:  Michael Ardelt; Yves Dittmar; Roland Kocijan; Jürgen Rödel; Birte Schulz; Hubert Scheuerlein; Utz Settmacher
Journal:  Int Wound J       Date:  2014-04-24       Impact factor: 3.315

Review 2.  Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.

Authors:  Marco Falcone; Ercole Concia; Massimo Giusti; Antonino Mazzone; Claudio Santini; Stefania Stefani; Francesco Violi
Journal:  Intern Emerg Med       Date:  2016-04-15       Impact factor: 3.397

3.  BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Alexandra Adler; Saira Chaudhry; Tamara Goldberg
Journal:  P T       Date:  2018-11

4.  Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells.

Authors:  Susan R Heimer; David J Evans; Michael E Stern; Joseph T Barbieri; Timothy Yahr; Suzanne M J Fleiszig
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

5.  Examination of hospital length of stay in Canada among patients with acute bacterial skin and skin structure infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  Michele H Potashman; Michael Stokes; Jieruo Liu; Robin Lawrence; Linda Harris
Journal:  Infect Drug Resist       Date:  2016-01-28       Impact factor: 4.003

Review 6.  Delafloxacin: design, development and potential place in therapy.

Authors:  Francisco Javier Candel; Marina Peñuelas
Journal:  Drug Des Devel Ther       Date:  2017-03-20       Impact factor: 4.162

7.  A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.

Authors:  William O'Riordan; Alison McManus; Juri Teras; Ivan Poromanski; Maria Cruz-Saldariagga; Megan Quintas; Laura Lawrence; ShuJui Liang; Sue Cammarata
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

8.  Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009.

Authors:  Jose A Suaya; Robertino M Mera; Adrian Cassidy; Patrick O'Hara; Heather Amrine-Madsen; Stuart Burstin; Loren G Miller
Journal:  BMC Infect Dis       Date:  2014-06-02       Impact factor: 3.090

9.  Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals.

Authors:  Kostas Athanasakis; Ioannis Petrakis; Mark Ollandezos; Christos Tsoulas; Dipen A Patel; Eleftheria Karampli; John Kyriopoulos
Journal:  Infect Dis Ther       Date:  2014-10-07

10.  Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.

Authors:  J Pullman; J Gardovskis; B Farley; E Sun; M Quintas; L Lawrence; R Ling; S Cammarata
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.